Patent ID: 9655857
Date: 2017-05-23
CPC Classifications: A61K,A61P

Claim:
1. A high-load solid tablet formulation comprising ibrutinib and one or more pharmaceutically acceptable excipients, wherein ibrutinib is a compound with the structure of Compound 1, and wherein the high-load solid tablet formulation comprises at least 50% w/w of ibrutinib, and the excipients comprise one or more diluents selected from the group consisting of lactose, sucrose, dextrose, dextrates, maltodextrin, mannitol, xylitol, sorbitol, cyclodextrins, calcium phosphate, calcium sulfate, starches, modified starches, cellulose, microcrystalline cellulose, microcellulose, and talc; one or more disintegrating agents selected from the group consisting of natural starch, a pregelatinized starch, a sodium starch, methylcrystalline cellulose, methylcellulose, croscarmellose, croscarmellose sodium, cross-linked sodium carboxymethylcellulose, cross-linked carboxymethylcellulose, cross-linked croscarmellose, cross-linked starch, cross-linked polymer, cross-linked polyvinylpyrrolidone, sodium alginate, a clay, and a gum; one or more binders selected from the group consisting of hydroxypropyl cellulose and polyvinylpyrrolidone; sodium laurel sulfate; silica; and magnesium stearate.